Nautilus Biotechnolgy
NAUT
72 hedge funds and large institutions have $245M invested in Nautilus Biotechnolgy in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 8 closing their positions.
223% more call options, than puts
Call options by funds: $1M | Put options by funds: $310K
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
29% more funds holding
Funds holding: 56 → 72 (+16)
1.56% more ownership
Funds ownership: 31.46% → 33.02% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
35% less capital invested
Capital invested by funds: $380M → $245M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$7.97M |
| 2 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$5.65M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.67M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.08M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$7.33M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.18M |
| 3 |
6CM
683 Capital Management
New York
|
-$2.7M |
| 4 |
CC
Casdin Capital
New York
|
-$2.19M |
| 5 |
Jane Street
New York
|
-$1.28M |
NAUT Hedge Fund Activity: Q3 2021 in Review
72 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2021, worth a combined $245M — down 35% from $380M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NAUT positions and 8 closed out — a net gain of 16 holders — while 19 added to existing stakes and 9 trimmed.
The largest buyer was Franklin Resources, adding an estimated $7.97M. The largest seller was Alyeska Investment Group, cutting an estimated $7.33M.
- 72 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2021, up from 56 in Q2 2021.
- Funds reported $245M of Nautilus Biotechnolgy stock for Q3 2021, down 35% quarter-over-quarter.
- 24 funds opened new Nautilus Biotechnolgy positions in Q3 2021 and 8 closed out, a net change of +16 holders.
- The largest Nautilus Biotechnolgy buyer in Q3 2021 was Franklin Resources, an estimated $7.97M added.
- The largest Nautilus Biotechnolgy seller in Q3 2021 was Alyeska Investment Group, an estimated $7.33M sold.
Based on aggregated 13F filings for Q3 2021.